Metabolism of Lipids in Advanced Cancer

Status Terminated

Clinical Trial Summary

The causes of failing nutrition status in advanced cancer are not well known. The way fat is moved, stored, burned or changed into other compounds may be affected and will be followed in patients using a tracer and other blood tests. The investigators hypothesize that fat loss and wasting results from low essential fatty acid availability in the body. Changes may occur in the liver that limits distribution and availability of fat to the body as an energy source or for other essential functions.

Clinical Trial Description

Weight loss in cancer is the result of breakdown of fat (lipid) and muscle protein reserves. This research will explore how people with cancer use fat in their body through the use of tracers and measures in the blood. A stable isotope of hydrogen called 'deuterium' is used to trace the production of different fats by the liver. Other methods will determine how much and what types of fat are transported around the body. Body composition will be determined by CT scan and related to fat measures. ;

Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00962234
Study type	Observational
Source	AHS Cancer Control Alberta
Contact
Status	Terminated
Phase	N/A
Start date	October 2009
Completion date	October 2011

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03357094` - Pulmonary Ventilation/Perfusion Imaging for the Prediction of Postoperative Residual Pulmonary Function	N/A
Recruiting	`NCT05543954` - 68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients	Early Phase 1
Completed	`NCT01114958` - Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases	Phase 1
Recruiting	`NCT06004440` - Real World Registry for Use of the Ion Endoluminal System
Completed	`NCT02926768` - Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors	Phase 1
Not yet recruiting	`NCT02907606` - Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study	N/A
Active, not recruiting	`NCT02514512` - Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking	N/A
Completed	`NCT02334007` - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery	Phase 1/Phase 2
Completed	`NCT02531737` - Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer	Phase 2
Active, not recruiting	`NCT02284633` - Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer
Completed	`NCT02106143` - RejuvenAir™ System Lobectomy Safety and Histology Study	N/A
Completed	`NCT01933789` - Improving Communication About Serious Illness	N/A
Enrolling by invitation	`NCT01687647` - Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure	Phase 3
Completed	`NCT00385177` - Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT00243685` - Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis	Phase 2/Phase 3
Terminated	`NCT00356525` - Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor	Phase 2
Completed	`NCT00351962` - Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours	N/A
Completed	`NCT00129844` - Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer	Phase 2
Withdrawn	`NCT00090701` - A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer	Phase 2
Recruiting	`NCT01789229` - Establishment of a Tumor Bank for Tissue Samples